激活GPCR,ORL1受体:一种新的治疗方法,可以预防心力衰竭的进展
Saliha Pathan1, Aarthi Pugazenthi1, Beverly Rea Dixon1
1Baylor College of Medicine.
Research square
|July 29, 2024
概括
使用MCOPPB激活ORL1受体在预防心肌梗塞后心力衰竭进展方面显示出有前途. 这种新的治疗方法改善了心脏功能,并减少了老鼠模型中的负重塑.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 缺血性心力衰竭 (HF) 是一个日益严重的全球健康问题,预防性治疗有限.
- 之前的研究表明, Gata4 过度表达可以改善心肌梗塞后的心脏功能,并可调节 ORL1 受体配体 Pnoc 基因.
研究的目的:
- 研究激活ORL1受体以抑制心力衰竭在老鼠缺血性心脏模型中的潜力.
- 评估ORL1激活剂MCOPPB对心脏功能和心肌梗塞后心肌梗塞重塑的治疗作用.
主要方法:
- 成年Sprague Dawley大鼠接受了冠状动脉绑定以诱导心肌梗塞.
- 大鼠每天接受MCOPPB (ORL1激活剂) 或盐水的腹腔内注射3个月,从结合后3周开始.
- 通过心声学评估心脏功能,并通过组织学分析心脏进行纤维化和血管生成.
主要成果:
- 与盐水相比,MCOPPB治疗在治疗后3个月显著改善了喷射分数 (67%与43%相比,p < 0.001).
- 组织学分析显示,MCOPPB减少了心脏纤维化,促进了血管生成.
- 在缺血性心力衰竭模型中,ORL1激活剂显示出显著的心脏保护作用.
结论:
- 使用MCOPPB激活ORL1受体代表了预防心力衰竭进展的潜在新疗法策略.
- 准ORL1受体可能为治疗缺血性心脏病及其并发症提供新的途径.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
01:21G-Protein Gated Ion Channels
4.6K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
4.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
01:12GPCR Desensitization
5.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.9K
01:30Transducer Mechanism: G Protein–Coupled Receptors
1.9K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.9K